ABSTRACT

Introduction: Non-invasive ventilation (NIV) in children has become an increasingly common modality of breathing support where pressure support is delivered through a mask interface or less commonly through other non-invasive interfaces. At this time, NIV is considered a first-line option for ventilatory support of chronic respiratory insufficiency associated with a range of respiratory and sleep disorders. Previous reviews on the effectiveness, complications and adherence to NIV treatment have lacked systematic methods. The purpose of this scoping review is to provide an overview of the evidence for the use of long-term NIV in children.

Methods and analysis: We will use previously established scoping methodology. Ten electronic databases will be searched to identify studies in children using NIV for longer than 3 months outside an intensive care setting. Grey literature search will include conference proceedings, theses and dissertations, unpublished trials, reports from regulatory agencies and manufacturers. Two reviewers will independently screen titles and abstracts for inclusion, followed by full-text screening of potentially relevant articles to determine final inclusion. Data synthesis will be performed at three levels: (1) an analysis of the number, publication type, publication year, and country of publication of the studies; (2) a summary of the study designs, outcomes measures used; (3) a thematic analysis of included studies by subgroups.

Ethics and dissemination: This study will provide a wide and rigorous overview of the evidence on the use of long-term NIV in children and provide critical information for healthcare professionals and policymakers to better care for this group of children. We will disseminate our findings through conference proceedings and publications, and evaluate the results for further systematic reviews and meta-analyses.

BACKGROUND

The purpose of this scoping review is to provide a rigorous overview of the evidence for the use of long-term non-invasive ventilation (NIV) in children with respiratory and/or sleep disorders. NIV in children is an increasingly common modality of breathing support where a mask interface, rather than an endotracheal tube or tracheostomy, is used to connect to pressure support. Long-term use of NIV provides an option for children who require intermittent ventilatory support (ie, for sleep only) or as part of palliative care. The use of NIV in children has expanded worldwide including developing countries, since its first reported use in the early 1990s, resulting in a decrease in the use of long-term invasive ventilation via tracheostomy1–4. Factors contributing to the increased use of NIV likely include increased survival of children with complex medical conditions, a shift in the emphasis of healthcare from hospital to home based care, and technological advances in the masks and machines to support home use of NIV in children.

Today, NIV is considered a first-line option of ventilatory support for chronic respiratory insufficiency associated with a range of respiratory and sleep disorders including...
chronic respiratory failure,12–14 cystic fibrosis15–18 musculoskeletal weakness or chest wall restriction,19–24 obstructive sleep apnoea (OSA) and craniofacial malformations,25–28 sleep disorders associated with neurological conditions and abnormalities in central respiratory drive.29–32 Long-term NIV has been used successfully in infants, from the first weeks of life. It has been shown NIV can be used long-term across all age groups.33–37 Safety and efficacy of NIV use in children have been documented for children with certain underlying conditions such as neuromuscular disease or OSA.38–40 Adherence to NIV therapy is also an outcome of interest as there are considerable challenges in establishing and maintaining use of NIV in children.41–46 Reported benefits of NIV use in children are broad and include outcomes related to acute illness,17 chronic respiratory function,18 23 48 sleep and daytime function,28 49 50 behaviour and neurocognitive outcomes,51 general health outcomes,20 quality of life,51 52 progression of underlying disease and survival.52 53 Funding for NIV and access to this technology are also important considerations.54

Previous reviews on long-term NIV use in children have lacked systematic methodology or NIV in children has been included in systematic reviews of broader topics. From a preliminary search strategy using terms related to NIV and children, we identified 758 review articles of which 91 may have some information relevant to long-term NIV use in children. Of these, only eight previous reviews described a search strategy or systematic methodology.32 55–61 Of note, none of the reviews had a specific focus of enquiry regarding long-term use of NIV in children but rather included NIV as one possible intervention for a particular paediatric population. Moreover, only four of these reviews had a specific section on NIV or included studies with NIV interventions. The aim of this scoping review is to define the body of literature relevant for the use of long-term NIV in children and provide a systematic overview of the existing evidence. Using this process, we will not only define the scope of existing data but also determine if there is sufficient literature relevant to subgroups that would be appropriate to apply systematic review or meta-analysis methodology.

Eligibility criteria

**Types of participants/population:** Studies reporting results for children from newborn to age 18 years will be included. Studies that include adults and children will be included if data for children is reported separately.

**Types of Interventions:** Eligible studies must contain information on NIV use defined as the administration of breathing support delivered through a non-invasive interface most commonly a nasal or face mask but also a mouth piece or abdominal belt. Types of breathing support includes (1) positive pressure support including continuous positive airway pressure (CPAP) or an inspiratory and expiratory airway pressure (bilevel), (2) negative pressure ventilation (NPV). Similar to the definition we found in other review articles from the preliminary search review, we will define long-term use as the use of NIV for at least 3 months outside an acute care environment. This may include, but not be limited to, use of NIV in community-based settings such as homes, a family or group home or specialised non-acute hospital based units. This definition is intended to include children with chronic conditions that require long-term NIV and are stable enough to receive ventilatory therapy at home or in a chronic care environment. Articles that describe long-term use of NIV with no time specification will be included if there is a clear intention of treating a chronic problem.

**Type of outcomes:** No restriction with regard to outcomes will be applied.

**Types of Studies:** Original studies published from 1990 onwards will be considered for inclusion including randomised and non-randomised clinical trials, controlled before-after studies, cross-sectional studies, longitudinal observational studies, retrospective cohorts, qualitative and mixed methods research and case series with three or more cases; 1990 was determined as a starting date because the first study of long-term NIV use in children we identified was published in 1993.

**Exclusion:** Case reports, case series with less than three subjects, comments, editorials, letters and reviews will be excluded. Studies where NIV is used solely for the treatment of acute illness will be excluded. During the full-text screening, only articles in English, French, Spanish, Portuguese, Italian and Catalan will be included as the review authors are proficient in those languages.

**Information sources:** An information specialist working for the Alberta Research Centre for Health Evidence (ARCHÉ) at the University of Alberta collaborated with investigators to design a comprehensive and sensitive
search strategy with terms for NIV and children from newborn to age 18 years. The search strategy (Box 1) was developed for Ovid Medline with a validated child search filter, and will be translated into Ovid Embase, PubMed (last year only), CINAHL via EbscoHOST, and Wiley Cochrane Library (including the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials, the Database of Abstracts of Reviews of Effects, the Health Technology Assessment Database, and the NHS Economic Evaluation Database).

Database search results will be limited to human studies published after 1990. No language or study design restrictions will be applied.

Reference lists of all studies selected for this scoping review will be scanned to identify further relevant studies not detected by the search strategy.

We will also search for grey literature (non-peer reviewed investigations) including conference proceedings, thesis and dissertations, unpublished trials, regulatory agencies and manufacturers reports. In consultation with the advisory team, a list of conference proceedings and annual meeting reports to review from January 2012
to December 2014 will be established. The information specialist will search websites of the conferences relevant to NIV such as the American Thoracic Society, the American College of Chest Physicians, the Canadian Thoracic Society, the European Respiratory Society, the American Academy of Sleep Medicine, the European Society of Sleep Research, the Australasian Sleep Association and the American Association of Neuromuscular and Electrodiagnostic Medicine. Investigators will search for publications of relevant proceeding abstracts or contact presenters to request study data if needed. ClinicalTrials.gov and the World Health Organisation’s International Clinical Trials Registry Platform will also be searched for trials registered after 2012 on NIV and positive airway pressure. Investigators will search for publications of relevant trials or attempt to contact study coordinators to request unpublished data. Regulatory agencies will be searched for ventilator device approval documents, premarket notifications, recall notices and safety advisories. Government sources will include Health Canada’s Medical Device Active License Listing (MDALL), the U.S. Food and Drug Administration (FDA) device website (Devices@FDA), the Australian Government’s Department of Health and Ageing Therapeutic Goods Administration (TGA) Database of Adverse Event Notifications, the European Medicines Agencies, and the New Zealand Medicines and Medical Devices Safety Authority (Medsafe: Medical Devices). Device manufacturers may be contacted with requests for premarket trial data. ProQuest Theses & Dissertations will also be searched for theses submitted after 1990 on NIV in children.

The Ovid Medline search strategy and the list of information sources will be approved by the advisory team prior to running the searches.

**Study records**

*Data management:* Results of searches will be imported into an EndNote library, and duplicates will be removed. Two exact copies of the EndNote library will be created for independent screening by two reviewers. *Selection process:* Two independent reviewers will screen titles and abstracts of retrieved articles for eligibility based on the inclusion criteria. The full text will be retrieved for all potentially relevant articles; each will be evaluated independently for eligibility by two reviewers. Discrepancies will be resolved through discussion between the reviewers to establish the final list of studies to be included in the scoping review. Reasons for exclusion will be recorded at the full-text review. *Data collection process:* Data extraction will be completed by one reviewer using a pre-designed standardised form and entered into Microsoft Excel database (Microsoft, Redmond, Washington, USA). Data extraction will be

<table>
<thead>
<tr>
<th>Table 1 Data extraction form</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study characteristics</strong></td>
</tr>
<tr>
<td>General information</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Introduction</td>
</tr>
<tr>
<td>Study research question</td>
</tr>
<tr>
<td>Design</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Outcomes measures (whether self-reported or objective tools)*</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Authors conclusions</td>
</tr>
</tbody>
</table>

*Units of measurements will be reported. NIV, non-invasive ventilation.*

verified by a second reviewer for a sample of 10% of the studies. The data extraction form is based on Bragge et al’s data extraction database and modified for this project to ensure that appropriate and relevant data is obtained (table 1). When there is missing information, two attempts to contact the corresponding authors will be made to obtain additional data. To avoid double counting in the instance of the same data set published in more than one publication, only one article per data set will be retained.

Data synthesis: The identified evidence will be collated using a specific analytical framework in order to present a narrative account of the existing literature.

Once the information has been extracted, we will present a narrative account of findings in three different ways: (1) a basic numerical analysis of the number, publication type, publication year and country of publication of the studies included in the review. (2) A narrative description of the study design, aims, participant characteristics, sample size, intervention type, control group description, outcomes measures, and statistical methods. We will use this information to establish subcategories of studies which may include grouping based on age (eg, infants, children, and adolescents), intervention type (eg, CPAP, bi-level, and NPV) and disease categories (eg, OSA, neuromuscular disease). (3) A thematic analysis of included studies by subgroups if appropriate. The results will be presented based on the priorities established by our advisory team including input from children using NIV and their caregivers.

Timeline: We anticipate finishing the search, screening, data extraction and synthesis within 6 months. A search update may be required if the timeline is longer than expected.

CONCLUSION

This scoping review will be the first, to our knowledge, to provide a systematic overview of the evidence on the use of long-term NIV in children. The findings from this review will provide stakeholders with a rigorous research base to support healthcare providers to improve clinical practice and policymakers to support resource needs for this complex group of children. We will disseminate our findings through conference proceedings and publications. The gathered data can be used to inform the development of guidelines for the care of children using long-term NIV and will identify gaps in knowledge to support future research endeavours. Based on the results, we will determine whether the application of other systematic review methodologies, such as meta-analysis or meta-synthesis, will be appropriate for any of the subgroups that we identify for future research.

REFERENCES


Department of Pediatrics, Hospital La Paz, Madrid, Spain
3. Department of Pediatrics, University of Ottawa and Children’s Hospital of Eastern Ontario, Ottawa, Ontario, Canada
4. Department of Respiratory Medicine, Great Ormond Street Hospital for Children, London, UK
5. Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada
6. Faculty of Dentistry, University of British Columbia, Vancouver, British Columbia, Canada
7. Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
8. Stollery Children’s Hospital, Edmonton, Alberta, Canada
9. Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada


